VM
VHCP Management II, LLC
13F filer · CIK 0001602263Last filed Feb 13, 2020
Inactive · not filing 13F
13F portfolio value$379MU.S. long equity reported on 13F
Positions187 new · 8 closed
Net flow last quarter-$46.6MBuys minus sells
Top 10 positions weight90.8%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q4 2019Reported Feb 13, 202018 positions | |||||
| $136M | 35.91% | 1.86% | Not reported | Q3 2019 | |
| $81.2M | 21.42% | 2.13% | -12.0% | Q1 2019 | |
| CICNSTConstar International Inc | $70.7M | 18.64% | Not reported | +106.5% | Q3 2018 |
| $25.2M | 6.64% | Not reported | -35.1% | Q2 2017 | |
| KPKALVKalVista Pharmaceuticals, Inc. | $6.52M | 1.72% | 2.05% | -2.8% | Q4 2016 |
| OOBSVObseva SA | $6.01M | 1.58% | 3.24% | -30.1% | Q2 2017 |
| MTMRSNMersana Therapeutics, Inc. | $5.29M | 1.39% | 2.03% | New | Q4 2019 |
| $4.56M | 1.20% | 2.47% | Not reported | Q4 2017 | |
| $4.48M | 1.18% | 0.79% | New | Q4 2019 | |
| ABADVMAdverum Biotechnologies, Inc. | $4.42M | 1.16% | 0.57% | Not reported | Q2 2016 |
| MPMRNSMarinus Pharmaceuticals, Inc. | $3.21M | 0.85% | 6.88% | Not reported | Q2 2018 |
| FSFTSVForty Seven, Inc. | $3.06M | 0.81% | 0.16% | New | Q4 2019 |
| $2.38M | 0.63% | 0.61% | Not reported | Q2 2019 | |
| $2.04M | 0.54% | 0.13% | New | Q4 2019 | |
| MSMYOVMyovant Sciences Ltd. | $1.19M | 0.31% | 0.09% | New | Q4 2019 |
| 8ETNB89bio, Inc. | $1.08M | 0.29% | 0.30% | New | Q4 2019 |
| BTBLPHBellerophon Therapeutics, Inc. | $230K | 0.06% | 14.39% | -84.1% | Q3 2017 |
| $227K | 0.06% | 0.12% | -92.5% | Q4 2018 | |
| Q3 2019Reported Nov 13, 201919 positions | |||||
| $90M | 34.31% | 1.86% | New | Q3 2019 | |
| $29.7M | 11.33% | Not reported | -26.0% | Q2 2017 | |
| $22.6M | 8.61% | 0.56% | -53.5% | Q4 2015 | |
| OOBSVObseva SA | $18.8M | 7.15% | 4.95% | Not reported | Q2 2017 |
| $18.1M | 6.89% | 2.59% | Not reported | Q1 2019 | |
| RPRARXRa Pharmaceuticals, Inc. | $16M | 6.10% | 1.44% | Not reported | Q4 2016 |
| $8.24M | 3.14% | 2.60% | Not reported | Q1 2016 | |
| $5.13M | 1.95% | 1.57% | Not reported | Q4 2018 | |
| $5.03M | 1.91% | 2.54% | Not reported | Q4 2017 | |
| CICNSTConstar International Inc | $4.69M | 1.79% | Not reported | Not reported | Q3 2018 |
| $4.6M | 1.75% | Not reported | -11.3% | Q2 2018 | |
| LJLJPCLa Jolla Pharmaceutical Co | $4.56M | 1.74% | 1.91% | Not reported | Q1 2019 |
| KPKALVKalVista Pharmaceuticals, Inc. | $4.37M | 1.67% | 2.12% | Not reported | Q4 2016 |
| TTCDATricida, Inc. | $3.67M | 1.40% | 0.24% | -72.3% | Q2 2018 |
| $2.77M | 1.06% | 0.61% | Not reported | Q2 2019 | |
| MPMRNSMarinus Pharmaceuticals, Inc. | $2.29M | 0.87% | 2.83% | +99.9% | Q2 2018 |
| BTBLPHBellerophon Therapeutics, Inc. | $2M | 0.76% | 6.02% | Not reported | Q3 2017 |
| RRRDUSRadius Recycling, Inc. | $352K | 0.13% | Not reported | New | Q3 2019 |
| PTPRVLPrevail Therapeutics Inc. | $32K | 0.01% | 0.01% | New | Q3 2019 |
| Q2 2019Reported Aug 13, 201919 positions | |||||
| $58.1M | 18.30% | 1.20% | Not reported | Q4 2015 | |
| $42.2M | 13.29% | Not reported | -15.4% | Q2 2017 | |
| OOBSVObseva SA | $25.5M | 8.03% | 4.95% | Not reported | Q2 2017 |
| $23M | 7.25% | 2.60% | +56.1% | Q1 2019 | |
| RPRARXRa Pharmaceuticals, Inc. | $20.4M | 6.42% | 1.60% | +7.1% | Q4 2016 |
| ZZGNXZogenix, Inc. | $17.3M | 5.45% | 0.85% | Not reported | Q3 2017 |
| TTCDATricida, Inc. | $16.9M | 5.33% | 0.87% | -55.5% | Q2 2018 |
| $10.9M | 3.43% | 2.60% | -11.5% | Q1 2016 | |
| CICNSTConstar International Inc | $8.92M | 2.81% | Not reported | Not reported | Q3 2018 |
| KPKALVKalVista Pharmaceuticals, Inc. | $8.35M | 2.63% | 2.18% | -34.3% | Q4 2016 |
| $8.25M | 2.60% | Not reported | -4.7% | Q2 2018 | |
| $5.46M | 1.72% | 2.54% | Not reported | Q4 2017 | |
| $5.17M | 1.63% | 1.71% | +57.3% | Q4 2018 | |
| LJLJPCLa Jolla Pharmaceutical Co | $4.79M | 1.51% | 1.91% | +39.5% | Q1 2019 |
| $4.03M | 1.27% | 0.61% | New | Q2 2019 | |
| MPMRNSMarinus Pharmaceuticals, Inc. | $3.09M | 0.97% | 1.42% | Not reported | Q2 2018 |
| BTBLPHBellerophon Therapeutics, Inc. | $2.49M | 0.79% | 6.02% | Not reported | Q3 2017 |
| KKDMNKadmon Holdings, Inc. | $514K | 0.16% | 0.19% | -69.6% | Q2 2018 |
| $382K | 0.12% | Not reported | -8.2% | Q3 2018 | |
| Q1 2019Reported May 14, 201918 positions | |||||
| $59.3M | 17.37% | 1.20% | Not reported | Q4 2015 | |
| $58.6M | 17.14% | Not reported | Not reported | Q2 2017 | |
| TTCDATricida, Inc. | $37.2M | 10.88% | 2.27% | 0.0% | Q2 2018 |
| OOBSVObseva SA | $28.8M | 8.43% | 4.95% | Not reported | Q2 2017 |
| $26.4M | 7.74% | 2.95% | Not reported | Q1 2016 | |
| ZZGNXZogenix, Inc. | $19.9M | 5.83% | 0.85% | Not reported | Q3 2017 |
| KPKALVKalVista Pharmaceuticals, Inc. | $16.4M | 4.80% | 3.33% | -24.5% | Q4 2016 |
| RPRARXRa Pharmaceuticals, Inc. | $14.2M | 4.15% | 1.50% | Not reported | Q4 2016 |
| $11.5M | 3.38% | Not reported | Not reported | Q2 2018 | |
| CICNSTConstar International Inc | $9.85M | 2.88% | Not reported | Not reported | Q3 2018 |
| $8.14M | 2.38% | 1.72% | New | Q1 2019 | |
| $6.07M | 1.78% | 2.73% | Not reported | Q4 2017 | |
| $3.41M | 1.00% | 1.16% | +8.5% | Q4 2018 | |
| MPMRNSMarinus Pharmaceuticals, Inc. | $3.11M | 0.91% | 1.42% | Not reported | Q2 2018 |
| BTBLPHBellerophon Therapeutics, Inc. | $2.71M | 0.79% | 6.02% | Not reported | Q3 2017 |
| LJLJPCLa Jolla Pharmaceutical Co | $2.39M | 0.70% | 1.37% | New | Q1 2019 |
| KKDMNKadmon Holdings, Inc. | $2.17M | 0.63% | 0.65% | -41.9% | Q2 2018 |
| $591K | 0.17% | Not reported | Not reported | Q3 2018 | |
Premium opens every quarter this fund has filed